Health Practices and Vaginal Microbicide Acceptability among Urban Black Women

2020 ◽  
Author(s):  
Lungwani Muungo

Background: Intravaginal topical microbicides are being investigated for prevention of HIV transmission. Useof vaginal microbicides will constitute a new type of practice, occurring in the context of other vaginal practicesrelated to contraception, hygiene, and self-care, which are affected by cultural norms and personal beliefs.Given the high rate of HIV infection among black women, research on practices and decision making relevantto microbicide acceptability is needed in this population.Methods: Twenty-three black women in New York City, aged 25–64, completed in-person semistructured interviewsand self-administered questionnaires. Quantitative analyses examined vaginal practices and willingnessto use microbicides. Qualitative analyses explored underlying decision-making processes involved inchoices regarding vaginal practices and general healthcare.Results: Willingness to use vaginal products for HIV prevention was high, especially among more educatedwomen. Safety was a major concern, and women were cautious about using vaginal products. Whereas someviewed synthetic products as having potentially harmful side effects, others perceived natural products as riskybecause of insufficient testing. Choices about vaginal practices were affected by assessments of risk and efficacy,prior experience, cultural background, and general approach to healthcare.Conclusions: The majority of women in the sample expressed willingness to use a vaginal product for HIV prevention.Decision-making processes regarding vaginal practices were complex and were affected by social, cultural,and personal factors. Although specific preferences may vary, attitudes toward using a vaginal productare likely to be positive when side effects are minimal and the product is considered safe.

2018 ◽  
Vol 38 (8) ◽  
pp. 1027-1039 ◽  
Author(s):  
Erin M. Ellis ◽  
William M.P. Klein ◽  
Edward Orehek ◽  
Rebecca A. Ferrer

Risk perceptions for a disease can motivate use of medications that reduce disease risk. However, these medications are often accompanied by elevated risks for other adverse health effects, and perceived risk of these side effects may also influence decisions. Emotions experienced at the time of a decision influence risk judgments and decision making, and they may be important to examine in these tradeoff contexts. This study examined the effect of experimentally induced fear and anger on risk perceptions and willingness to use a hypothetical medical treatment that attenuates risk of one condition but increases the risk for another. Participants ( N = 1948) completed an induction of fear, anger, or neutral emotion and then read about a hypothetical medication that reduced risk for one health condition but increased risk for another, and they indicated their willingness to use it. Deliberative, experiential, and affective risk perceptions about both health conditions were measured, conditional on taking and not taking the medication. Fear condition participants were more willing to take the medication than those in the neutral condition (β = 0.14; P = 0.009; 95% confidence interval, 0.036–0.25). Fear also increased deliberative, experiential, and affective risk when conditioned on not using the medication, Ps < 0.05. In contrast, anger did not influence willingness to use the medication ( P = 0.22) and increased deliberative and affective risk of side effects when conditioned on using the medication ( P < 0.05). As one of the first studies to examine how emotion influences tradeoff decision making, these findings extend our understanding of how fear and anger influence such decisions.


1979 ◽  
Author(s):  
F Albert ◽  
U Schmidt

The effect of sulfinpyrazone (200 mg three times a day) and acetylsalicylic acid (500 mg three times a day) on the incidence of thrombosis of arteriovenous shunts was investigated in a controlled clinical trial. In 36 patients with chronic renal failure scheduled to begin haemodialysis the same operating team constructed a subcutaneous fistula in the distal forearm. During the first six weeks after the operation the antithrombotic efficacy proved to be good for both substances. No differences of thrombotic events between the two treatment groups were statistically significant. But in contrast to acetylsalicylic acid sulfinpyrazone made no significant inhibition of platelet - aggregation; sulfinpyrazone probably will prevent the clot formation by prolonging the shortened platelet survival in uraemic patients. In a high rate of patients given acetylsalicylic acid (10 out of 17) there were local bleeding and gastrointestinal side effects. In consequence we should prefer sulfinpyrazone, because in the sulfinpyrazone group side effects were minimal and in none patient withdrawal from the study was necessitated.


Author(s):  
Iris E. Beldhuis ◽  
Ramesh S. Marapin ◽  
You Yuan Jiang ◽  
Nádia F. Simões de Souza ◽  
Artemis Georgiou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document